Global Pulmonary Embolism Drug Market

Pulmonary Embolism Drug Comprehensive Study by Type (DS-9231, DS-1040, TRX-1, Others), Application (Hospital, Clinic, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug Class (Factor Xa Inhibitor, Low Molecular Weight Heparin, P2Y12 Platelet Inhibitor, Others), Indictaion (Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis, Others) Players and Region - Global Market Outlook to 2030

Pulmonary Embolism Drug Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Pulmonary Embolism Drug
According to the Centers for Disease Control and Prevention estimation, there are around 900,000 people afflicted by Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT), 1 or 2 per 1,000 individuals each year are affected in the United States. PE is a sudden blockage in a lung artery which is caused by a blood clot that travels to the lung from a vein in the leg, also known as deep vein thrombosis. A clot that forms in one part of the body and travels in the bloodstream to another part of the body is called an embolus. Medication for the treatment includes anticoagulants drugs and thrombin inhibitors drugs. These drugs decrease the clotting power of blood and consequently, the chances of thrombosis events, such as pulmonary embolism, decreases. These drugs are also available in the form of injection, capsule, and tablet. Further, the Growing consumption of alcohol and tobacco with overweight and obesity adds a risk of developing high blood pressure leading to thrombosis. These factors are driving the Global Pulmonary Embolism Market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR9.0%


The market is fragmented and the Key players are focusing on the development of drugs with better efficacy. Moreover, Companies are focused on developing low-cost drugs to serve the large pulmonary embolism patients pool across the globe. Such key developments are likely to fuel the Global Thrombosis Drugs market in the near future. For Instance, In June 2018, Biogen entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007, a plasminogen inhibitor, and backup compounds. TMS-007 is a plasminogen activator with a novel mechanism of action associated with breaking down blood clots and is believed to inhibit local inflammation at the site of thrombosis. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Pulmonary Embolism Drug market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline plc (United Kingdom), Johnson & Johnson (United States), Accu-Break Pharmaceuticals, Inc (United States), Dong-A Socio Holdings Co. Ltd.(South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Genentech, Inc. (United States), Aspen Pharmacare Holdings Limited (South Africa) and Pfizer Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Verseon Corporation (United States), Cyclopharm Ltd.(Australia), Jubilant Lifesciences Ltd.(India), Siemens Medical Solutions, Inc (United States) and Grifols Therapeutics Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Pulmonary Embolism Drug market by Type (DS-9231, DS-1040, TRX-1 and Others), Application (Hospital, Clinic and Others) and Region.



On the basis of geography, the market of Pulmonary Embolism Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Pulmonary Embolism Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Factor Xa Inhibitor will boost the Pulmonary Embolism Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indictaion, the sub-segment i.e. Pulmonary Embolism will boost the Pulmonary Embolism Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increase in Health Care Spending and Demand for Better Treatment in Emerging Economies

Market Growth Drivers:
Increasing Awareness about the Available Drugs & Treatment, The Upsurge in the Burden of Cardiovascular Disease & Trauma Cases and Growing Geriatric & Obese Population

Challenges:
Lack of Awareness about Thromboembolism Conditions

Restraints:
Availability of Generic Drugs and High Price of Non-Vitamin K Oral Anticoagulant Drugs

Opportunities:
Unmet Needs for the Pulmonary Embolism Market and Rapid Technological Advancements in the Treatment Therapies

Market Leaders and their expansionary development strategies
In February 2019, Grifols Therapeutics Inc., a United States based biotechnology company launched AT- lll, a new type of human recombinant thrombosis drugs for the indication of cardiac surgery cardiopulmonary bypass.
In January 2023, Alameda, Calif.-based global healthcare company Penumbra has announced U.S. Food & Drug Administration (FDA) clearance and launch of Lightning Flash, its advanced mechanical thrombectomy system which addresses venous and pulmonary thrombus.
December 2017, Aurobindo Pharma received the Food and Drug Administration approval to manufacture and market its generic version of Fondaparinux Sodium injection used to prevent Pulmonary Embolism.

Key Target Audience
Pulmonary Embolism Drug Manufacturers, Pharmaceutical Companies, Government and Regulatory Bodies, Health Care Industries, Potential Investors, Downstream Vendors, Academic and Research Institute and Research Organizations

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • DS-9231
  • DS-1040
  • TRX-1
  • Others
By Application
  • Hospital
  • Clinic
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Drug Class
  • Factor Xa Inhibitor
  • Low Molecular Weight Heparin
  • P2Y12 Platelet Inhibitor
  • Others

By Indictaion
  • Pulmonary Embolism
  • Atrial Fibrillation
  • Deep Vein Thrombosis
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Awareness about the Available Drugs & Treatment
      • 3.2.2. The Upsurge in the Burden of Cardiovascular Disease & Trauma Cases
      • 3.2.3. Growing Geriatric & Obese Population
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness about Thromboembolism Conditions
    • 3.4. Market Trends
      • 3.4.1. Increase in Health Care Spending
      • 3.4.2. Demand for Better Treatment in Emerging Economies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pulmonary Embolism Drug, by Type, Application, Distribution Channel, Drug Class, Indictaion and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Pulmonary Embolism Drug (Value)
      • 5.2.1. Global Pulmonary Embolism Drug by: Type (Value)
        • 5.2.1.1. DS-9231
        • 5.2.1.2. DS-1040
        • 5.2.1.3. TRX-1
        • 5.2.1.4. Others
      • 5.2.2. Global Pulmonary Embolism Drug by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Others
      • 5.2.3. Global Pulmonary Embolism Drug by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Pulmonary Embolism Drug by: Drug Class (Value)
        • 5.2.4.1. Factor Xa Inhibitor
        • 5.2.4.2. Low Molecular Weight Heparin
        • 5.2.4.3. P2Y12 Platelet Inhibitor
        • 5.2.4.4. Others
      • 5.2.5. Global Pulmonary Embolism Drug by: Indictaion (Value)
        • 5.2.5.1. Pulmonary Embolism
        • 5.2.5.2. Atrial Fibrillation
        • 5.2.5.3. Deep Vein Thrombosis
        • 5.2.5.4. Others
      • 5.2.6. Global Pulmonary Embolism Drug Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Pulmonary Embolism Drug (Volume)
      • 5.3.1. Global Pulmonary Embolism Drug by: Type (Volume)
        • 5.3.1.1. DS-9231
        • 5.3.1.2. DS-1040
        • 5.3.1.3. TRX-1
        • 5.3.1.4. Others
      • 5.3.2. Global Pulmonary Embolism Drug by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinic
        • 5.3.2.3. Others
      • 5.3.3. Global Pulmonary Embolism Drug by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online Pharmacies
      • 5.3.4. Global Pulmonary Embolism Drug by: Drug Class (Volume)
        • 5.3.4.1. Factor Xa Inhibitor
        • 5.3.4.2. Low Molecular Weight Heparin
        • 5.3.4.3. P2Y12 Platelet Inhibitor
        • 5.3.4.4. Others
      • 5.3.5. Global Pulmonary Embolism Drug by: Indictaion (Volume)
        • 5.3.5.1. Pulmonary Embolism
        • 5.3.5.2. Atrial Fibrillation
        • 5.3.5.3. Deep Vein Thrombosis
        • 5.3.5.4. Others
      • 5.3.6. Global Pulmonary Embolism Drug Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Pulmonary Embolism Drug (Price)
      • 5.4.1. Global Pulmonary Embolism Drug by: Type (Price)
  • 6. Pulmonary Embolism Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Accu-Break Pharmaceuticals, Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Dong-A Socio Holdings Co. Ltd.(South Korea)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genentech, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Aspen Pharmacare Holdings Limited (South Africa)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Pulmonary Embolism Drug Sale, by Type, Application, Distribution Channel, Drug Class, Indictaion and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Pulmonary Embolism Drug (Value)
      • 7.2.1. Global Pulmonary Embolism Drug by: Type (Value)
        • 7.2.1.1. DS-9231
        • 7.2.1.2. DS-1040
        • 7.2.1.3. TRX-1
        • 7.2.1.4. Others
      • 7.2.2. Global Pulmonary Embolism Drug by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Others
      • 7.2.3. Global Pulmonary Embolism Drug by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Pulmonary Embolism Drug by: Drug Class (Value)
        • 7.2.4.1. Factor Xa Inhibitor
        • 7.2.4.2. Low Molecular Weight Heparin
        • 7.2.4.3. P2Y12 Platelet Inhibitor
        • 7.2.4.4. Others
      • 7.2.5. Global Pulmonary Embolism Drug by: Indictaion (Value)
        • 7.2.5.1. Pulmonary Embolism
        • 7.2.5.2. Atrial Fibrillation
        • 7.2.5.3. Deep Vein Thrombosis
        • 7.2.5.4. Others
      • 7.2.6. Global Pulmonary Embolism Drug Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Pulmonary Embolism Drug (Volume)
      • 7.3.1. Global Pulmonary Embolism Drug by: Type (Volume)
        • 7.3.1.1. DS-9231
        • 7.3.1.2. DS-1040
        • 7.3.1.3. TRX-1
        • 7.3.1.4. Others
      • 7.3.2. Global Pulmonary Embolism Drug by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinic
        • 7.3.2.3. Others
      • 7.3.3. Global Pulmonary Embolism Drug by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online Pharmacies
      • 7.3.4. Global Pulmonary Embolism Drug by: Drug Class (Volume)
        • 7.3.4.1. Factor Xa Inhibitor
        • 7.3.4.2. Low Molecular Weight Heparin
        • 7.3.4.3. P2Y12 Platelet Inhibitor
        • 7.3.4.4. Others
      • 7.3.5. Global Pulmonary Embolism Drug by: Indictaion (Volume)
        • 7.3.5.1. Pulmonary Embolism
        • 7.3.5.2. Atrial Fibrillation
        • 7.3.5.3. Deep Vein Thrombosis
        • 7.3.5.4. Others
      • 7.3.6. Global Pulmonary Embolism Drug Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Pulmonary Embolism Drug (Price)
      • 7.4.1. Global Pulmonary Embolism Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pulmonary Embolism Drug: by Type(USD Million)
  • Table 2. Pulmonary Embolism Drug DS-9231 , by Region USD Million (2018-2023)
  • Table 3. Pulmonary Embolism Drug DS-1040 , by Region USD Million (2018-2023)
  • Table 4. Pulmonary Embolism Drug TRX-1 , by Region USD Million (2018-2023)
  • Table 5. Pulmonary Embolism Drug Others , by Region USD Million (2018-2023)
  • Table 6. Pulmonary Embolism Drug: by Application(USD Million)
  • Table 7. Pulmonary Embolism Drug Hospital , by Region USD Million (2018-2023)
  • Table 8. Pulmonary Embolism Drug Clinic , by Region USD Million (2018-2023)
  • Table 9. Pulmonary Embolism Drug Others , by Region USD Million (2018-2023)
  • Table 10. Pulmonary Embolism Drug: by Distribution Channel(USD Million)
  • Table 11. Pulmonary Embolism Drug Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 12. Pulmonary Embolism Drug Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 13. Pulmonary Embolism Drug Online Pharmacies , by Region USD Million (2018-2023)
  • Table 14. Pulmonary Embolism Drug: by Drug Class(USD Million)
  • Table 15. Pulmonary Embolism Drug Factor Xa Inhibitor , by Region USD Million (2018-2023)
  • Table 16. Pulmonary Embolism Drug Low Molecular Weight Heparin , by Region USD Million (2018-2023)
  • Table 17. Pulmonary Embolism Drug P2Y12 Platelet Inhibitor , by Region USD Million (2018-2023)
  • Table 18. Pulmonary Embolism Drug Others , by Region USD Million (2018-2023)
  • Table 19. Pulmonary Embolism Drug: by Indictaion(USD Million)
  • Table 20. Pulmonary Embolism Drug Pulmonary Embolism , by Region USD Million (2018-2023)
  • Table 21. Pulmonary Embolism Drug Atrial Fibrillation , by Region USD Million (2018-2023)
  • Table 22. Pulmonary Embolism Drug Deep Vein Thrombosis , by Region USD Million (2018-2023)
  • Table 23. Pulmonary Embolism Drug Others , by Region USD Million (2018-2023)
  • Table 24. South America Pulmonary Embolism Drug, by Country USD Million (2018-2023)
  • Table 25. South America Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 26. South America Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 27. South America Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 28. South America Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 29. South America Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 30. Brazil Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 31. Brazil Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 32. Brazil Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 33. Brazil Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 34. Brazil Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 35. Argentina Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 36. Argentina Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 37. Argentina Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 38. Argentina Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 39. Argentina Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 40. Rest of South America Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 41. Rest of South America Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 42. Rest of South America Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 43. Rest of South America Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 44. Rest of South America Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 45. Asia Pacific Pulmonary Embolism Drug, by Country USD Million (2018-2023)
  • Table 46. Asia Pacific Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 47. Asia Pacific Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 48. Asia Pacific Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 49. Asia Pacific Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 50. Asia Pacific Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 51. China Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 52. China Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 53. China Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 54. China Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 55. China Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 56. Japan Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 57. Japan Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 58. Japan Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 59. Japan Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 60. Japan Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 61. India Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 62. India Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 63. India Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 64. India Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 65. India Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 66. South Korea Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 67. South Korea Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 68. South Korea Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 69. South Korea Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 70. South Korea Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 71. Taiwan Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 72. Taiwan Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 73. Taiwan Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 74. Taiwan Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 75. Taiwan Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 76. Australia Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 77. Australia Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 78. Australia Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 79. Australia Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 80. Australia Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 86. Europe Pulmonary Embolism Drug, by Country USD Million (2018-2023)
  • Table 87. Europe Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 88. Europe Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 89. Europe Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 90. Europe Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 91. Europe Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 92. Germany Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 93. Germany Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 94. Germany Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 95. Germany Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 96. Germany Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 97. France Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 98. France Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 99. France Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 100. France Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 101. France Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 102. Italy Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 103. Italy Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 104. Italy Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 105. Italy Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 106. Italy Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 107. United Kingdom Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 108. United Kingdom Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 109. United Kingdom Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 110. United Kingdom Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 111. United Kingdom Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 112. Netherlands Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 113. Netherlands Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 114. Netherlands Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 115. Netherlands Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 116. Netherlands Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 117. Rest of Europe Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 118. Rest of Europe Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 119. Rest of Europe Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 120. Rest of Europe Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 121. Rest of Europe Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 122. MEA Pulmonary Embolism Drug, by Country USD Million (2018-2023)
  • Table 123. MEA Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 124. MEA Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 125. MEA Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 126. MEA Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 127. MEA Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 128. Middle East Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 129. Middle East Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 130. Middle East Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 131. Middle East Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 132. Middle East Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 133. Africa Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 134. Africa Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 135. Africa Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 136. Africa Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 137. Africa Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 138. North America Pulmonary Embolism Drug, by Country USD Million (2018-2023)
  • Table 139. North America Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 140. North America Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 141. North America Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 142. North America Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 143. North America Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 144. United States Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 145. United States Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 146. United States Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 147. United States Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 148. United States Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 149. Canada Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 150. Canada Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 151. Canada Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 152. Canada Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 153. Canada Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 154. Mexico Pulmonary Embolism Drug, by Type USD Million (2018-2023)
  • Table 155. Mexico Pulmonary Embolism Drug, by Application USD Million (2018-2023)
  • Table 156. Mexico Pulmonary Embolism Drug, by Distribution Channel USD Million (2018-2023)
  • Table 157. Mexico Pulmonary Embolism Drug, by Drug Class USD Million (2018-2023)
  • Table 158. Mexico Pulmonary Embolism Drug, by Indictaion USD Million (2018-2023)
  • Table 159. Pulmonary Embolism Drug Sales: by Type(K Units)
  • Table 160. Pulmonary Embolism Drug Sales DS-9231 , by Region K Units (2018-2023)
  • Table 161. Pulmonary Embolism Drug Sales DS-1040 , by Region K Units (2018-2023)
  • Table 162. Pulmonary Embolism Drug Sales TRX-1 , by Region K Units (2018-2023)
  • Table 163. Pulmonary Embolism Drug Sales Others , by Region K Units (2018-2023)
  • Table 164. Pulmonary Embolism Drug Sales: by Application(K Units)
  • Table 165. Pulmonary Embolism Drug Sales Hospital , by Region K Units (2018-2023)
  • Table 166. Pulmonary Embolism Drug Sales Clinic , by Region K Units (2018-2023)
  • Table 167. Pulmonary Embolism Drug Sales Others , by Region K Units (2018-2023)
  • Table 168. Pulmonary Embolism Drug Sales: by Distribution Channel(K Units)
  • Table 169. Pulmonary Embolism Drug Sales Hospital Pharmacies , by Region K Units (2018-2023)
  • Table 170. Pulmonary Embolism Drug Sales Retail Pharmacies , by Region K Units (2018-2023)
  • Table 171. Pulmonary Embolism Drug Sales Online Pharmacies , by Region K Units (2018-2023)
  • Table 172. Pulmonary Embolism Drug Sales: by Drug Class(K Units)
  • Table 173. Pulmonary Embolism Drug Sales Factor Xa Inhibitor , by Region K Units (2018-2023)
  • Table 174. Pulmonary Embolism Drug Sales Low Molecular Weight Heparin , by Region K Units (2018-2023)
  • Table 175. Pulmonary Embolism Drug Sales P2Y12 Platelet Inhibitor , by Region K Units (2018-2023)
  • Table 176. Pulmonary Embolism Drug Sales Others , by Region K Units (2018-2023)
  • Table 177. Pulmonary Embolism Drug Sales: by Indictaion(K Units)
  • Table 178. Pulmonary Embolism Drug Sales Pulmonary Embolism , by Region K Units (2018-2023)
  • Table 179. Pulmonary Embolism Drug Sales Atrial Fibrillation , by Region K Units (2018-2023)
  • Table 180. Pulmonary Embolism Drug Sales Deep Vein Thrombosis , by Region K Units (2018-2023)
  • Table 181. Pulmonary Embolism Drug Sales Others , by Region K Units (2018-2023)
  • Table 182. South America Pulmonary Embolism Drug Sales, by Country K Units (2018-2023)
  • Table 183. South America Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 184. South America Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 185. South America Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 186. South America Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 187. South America Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 188. Brazil Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 189. Brazil Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 190. Brazil Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 191. Brazil Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 192. Brazil Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 193. Argentina Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 194. Argentina Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 195. Argentina Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 196. Argentina Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 197. Argentina Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 198. Rest of South America Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 199. Rest of South America Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 200. Rest of South America Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 201. Rest of South America Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 202. Rest of South America Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 203. Asia Pacific Pulmonary Embolism Drug Sales, by Country K Units (2018-2023)
  • Table 204. Asia Pacific Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 205. Asia Pacific Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 206. Asia Pacific Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 207. Asia Pacific Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 208. Asia Pacific Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 209. China Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 210. China Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 211. China Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 212. China Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 213. China Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 214. Japan Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 215. Japan Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 216. Japan Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 217. Japan Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 218. Japan Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 219. India Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 220. India Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 221. India Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 222. India Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 223. India Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 224. South Korea Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 225. South Korea Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 226. South Korea Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 227. South Korea Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 228. South Korea Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 229. Taiwan Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 230. Taiwan Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 231. Taiwan Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 232. Taiwan Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 233. Taiwan Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 234. Australia Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 235. Australia Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 236. Australia Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 237. Australia Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 238. Australia Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 239. Rest of Asia-Pacific Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 240. Rest of Asia-Pacific Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 241. Rest of Asia-Pacific Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 242. Rest of Asia-Pacific Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 243. Rest of Asia-Pacific Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 244. Europe Pulmonary Embolism Drug Sales, by Country K Units (2018-2023)
  • Table 245. Europe Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 246. Europe Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 247. Europe Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 248. Europe Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 249. Europe Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 250. Germany Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 251. Germany Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 252. Germany Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 253. Germany Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 254. Germany Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 255. France Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 256. France Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 257. France Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 258. France Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 259. France Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 260. Italy Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 261. Italy Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 262. Italy Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 263. Italy Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 264. Italy Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 265. United Kingdom Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 266. United Kingdom Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 267. United Kingdom Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 268. United Kingdom Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 269. United Kingdom Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 270. Netherlands Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 271. Netherlands Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 272. Netherlands Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 273. Netherlands Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 274. Netherlands Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 275. Rest of Europe Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 276. Rest of Europe Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 277. Rest of Europe Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 278. Rest of Europe Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 279. Rest of Europe Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 280. MEA Pulmonary Embolism Drug Sales, by Country K Units (2018-2023)
  • Table 281. MEA Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 282. MEA Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 283. MEA Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 284. MEA Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 285. MEA Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 286. Middle East Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 287. Middle East Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 288. Middle East Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 289. Middle East Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 290. Middle East Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 291. Africa Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 292. Africa Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 293. Africa Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 294. Africa Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 295. Africa Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 296. North America Pulmonary Embolism Drug Sales, by Country K Units (2018-2023)
  • Table 297. North America Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 298. North America Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 299. North America Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 300. North America Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 301. North America Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 302. United States Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 303. United States Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 304. United States Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 305. United States Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 306. United States Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 307. Canada Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 308. Canada Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 309. Canada Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 310. Canada Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 311. Canada Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 312. Mexico Pulmonary Embolism Drug Sales, by Type K Units (2018-2023)
  • Table 313. Mexico Pulmonary Embolism Drug Sales, by Application K Units (2018-2023)
  • Table 314. Mexico Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 315. Mexico Pulmonary Embolism Drug Sales, by Drug Class K Units (2018-2023)
  • Table 316. Mexico Pulmonary Embolism Drug Sales, by Indictaion K Units (2018-2023)
  • Table 317. Pulmonary Embolism Drug: by Type(USD/Units)
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Pulmonary Embolism Drug: by Type(USD Million)
  • Table 327. Pulmonary Embolism Drug DS-9231 , by Region USD Million (2025-2030)
  • Table 328. Pulmonary Embolism Drug DS-1040 , by Region USD Million (2025-2030)
  • Table 329. Pulmonary Embolism Drug TRX-1 , by Region USD Million (2025-2030)
  • Table 330. Pulmonary Embolism Drug Others , by Region USD Million (2025-2030)
  • Table 331. Pulmonary Embolism Drug: by Application(USD Million)
  • Table 332. Pulmonary Embolism Drug Hospital , by Region USD Million (2025-2030)
  • Table 333. Pulmonary Embolism Drug Clinic , by Region USD Million (2025-2030)
  • Table 334. Pulmonary Embolism Drug Others , by Region USD Million (2025-2030)
  • Table 335. Pulmonary Embolism Drug: by Distribution Channel(USD Million)
  • Table 336. Pulmonary Embolism Drug Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 337. Pulmonary Embolism Drug Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 338. Pulmonary Embolism Drug Online Pharmacies , by Region USD Million (2025-2030)
  • Table 339. Pulmonary Embolism Drug: by Drug Class(USD Million)
  • Table 340. Pulmonary Embolism Drug Factor Xa Inhibitor , by Region USD Million (2025-2030)
  • Table 341. Pulmonary Embolism Drug Low Molecular Weight Heparin , by Region USD Million (2025-2030)
  • Table 342. Pulmonary Embolism Drug P2Y12 Platelet Inhibitor , by Region USD Million (2025-2030)
  • Table 343. Pulmonary Embolism Drug Others , by Region USD Million (2025-2030)
  • Table 344. Pulmonary Embolism Drug: by Indictaion(USD Million)
  • Table 345. Pulmonary Embolism Drug Pulmonary Embolism , by Region USD Million (2025-2030)
  • Table 346. Pulmonary Embolism Drug Atrial Fibrillation , by Region USD Million (2025-2030)
  • Table 347. Pulmonary Embolism Drug Deep Vein Thrombosis , by Region USD Million (2025-2030)
  • Table 348. Pulmonary Embolism Drug Others , by Region USD Million (2025-2030)
  • Table 349. South America Pulmonary Embolism Drug, by Country USD Million (2025-2030)
  • Table 350. South America Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 351. South America Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 352. South America Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 353. South America Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 354. South America Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 355. Brazil Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 356. Brazil Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 357. Brazil Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 358. Brazil Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 359. Brazil Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 360. Argentina Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 361. Argentina Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 362. Argentina Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 363. Argentina Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 364. Argentina Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 365. Rest of South America Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 366. Rest of South America Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 367. Rest of South America Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 368. Rest of South America Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 369. Rest of South America Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 370. Asia Pacific Pulmonary Embolism Drug, by Country USD Million (2025-2030)
  • Table 371. Asia Pacific Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 372. Asia Pacific Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 373. Asia Pacific Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 374. Asia Pacific Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 375. Asia Pacific Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 376. China Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 377. China Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 378. China Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 379. China Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 380. China Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 381. Japan Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 382. Japan Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 383. Japan Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 384. Japan Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 385. Japan Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 386. India Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 387. India Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 388. India Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 389. India Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 390. India Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 391. South Korea Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 392. South Korea Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 393. South Korea Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 394. South Korea Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 395. South Korea Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 396. Taiwan Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 397. Taiwan Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 398. Taiwan Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 399. Taiwan Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 400. Taiwan Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 401. Australia Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 402. Australia Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 403. Australia Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 404. Australia Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 405. Australia Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 406. Rest of Asia-Pacific Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 407. Rest of Asia-Pacific Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 408. Rest of Asia-Pacific Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 409. Rest of Asia-Pacific Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 410. Rest of Asia-Pacific Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 411. Europe Pulmonary Embolism Drug, by Country USD Million (2025-2030)
  • Table 412. Europe Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 413. Europe Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 414. Europe Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 415. Europe Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 416. Europe Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 417. Germany Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 418. Germany Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 419. Germany Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 420. Germany Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 421. Germany Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 422. France Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 423. France Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 424. France Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 425. France Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 426. France Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 427. Italy Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 428. Italy Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 429. Italy Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 430. Italy Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 431. Italy Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 432. United Kingdom Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 433. United Kingdom Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 434. United Kingdom Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 435. United Kingdom Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 436. United Kingdom Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 437. Netherlands Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 438. Netherlands Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 439. Netherlands Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 440. Netherlands Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 441. Netherlands Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 442. Rest of Europe Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 443. Rest of Europe Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 444. Rest of Europe Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 445. Rest of Europe Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 446. Rest of Europe Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 447. MEA Pulmonary Embolism Drug, by Country USD Million (2025-2030)
  • Table 448. MEA Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 449. MEA Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 450. MEA Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 451. MEA Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 452. MEA Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 453. Middle East Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 454. Middle East Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 455. Middle East Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 456. Middle East Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 457. Middle East Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 458. Africa Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 459. Africa Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 460. Africa Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 461. Africa Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 462. Africa Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 463. North America Pulmonary Embolism Drug, by Country USD Million (2025-2030)
  • Table 464. North America Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 465. North America Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 466. North America Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 467. North America Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 468. North America Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 469. United States Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 470. United States Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 471. United States Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 472. United States Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 473. United States Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 474. Canada Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 475. Canada Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 476. Canada Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 477. Canada Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 478. Canada Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 479. Mexico Pulmonary Embolism Drug, by Type USD Million (2025-2030)
  • Table 480. Mexico Pulmonary Embolism Drug, by Application USD Million (2025-2030)
  • Table 481. Mexico Pulmonary Embolism Drug, by Distribution Channel USD Million (2025-2030)
  • Table 482. Mexico Pulmonary Embolism Drug, by Drug Class USD Million (2025-2030)
  • Table 483. Mexico Pulmonary Embolism Drug, by Indictaion USD Million (2025-2030)
  • Table 484. Pulmonary Embolism Drug Sales: by Type(K Units)
  • Table 485. Pulmonary Embolism Drug Sales DS-9231 , by Region K Units (2025-2030)
  • Table 486. Pulmonary Embolism Drug Sales DS-1040 , by Region K Units (2025-2030)
  • Table 487. Pulmonary Embolism Drug Sales TRX-1 , by Region K Units (2025-2030)
  • Table 488. Pulmonary Embolism Drug Sales Others , by Region K Units (2025-2030)
  • Table 489. Pulmonary Embolism Drug Sales: by Application(K Units)
  • Table 490. Pulmonary Embolism Drug Sales Hospital , by Region K Units (2025-2030)
  • Table 491. Pulmonary Embolism Drug Sales Clinic , by Region K Units (2025-2030)
  • Table 492. Pulmonary Embolism Drug Sales Others , by Region K Units (2025-2030)
  • Table 493. Pulmonary Embolism Drug Sales: by Distribution Channel(K Units)
  • Table 494. Pulmonary Embolism Drug Sales Hospital Pharmacies , by Region K Units (2025-2030)
  • Table 495. Pulmonary Embolism Drug Sales Retail Pharmacies , by Region K Units (2025-2030)
  • Table 496. Pulmonary Embolism Drug Sales Online Pharmacies , by Region K Units (2025-2030)
  • Table 497. Pulmonary Embolism Drug Sales: by Drug Class(K Units)
  • Table 498. Pulmonary Embolism Drug Sales Factor Xa Inhibitor , by Region K Units (2025-2030)
  • Table 499. Pulmonary Embolism Drug Sales Low Molecular Weight Heparin , by Region K Units (2025-2030)
  • Table 500. Pulmonary Embolism Drug Sales P2Y12 Platelet Inhibitor , by Region K Units (2025-2030)
  • Table 501. Pulmonary Embolism Drug Sales Others , by Region K Units (2025-2030)
  • Table 502. Pulmonary Embolism Drug Sales: by Indictaion(K Units)
  • Table 503. Pulmonary Embolism Drug Sales Pulmonary Embolism , by Region K Units (2025-2030)
  • Table 504. Pulmonary Embolism Drug Sales Atrial Fibrillation , by Region K Units (2025-2030)
  • Table 505. Pulmonary Embolism Drug Sales Deep Vein Thrombosis , by Region K Units (2025-2030)
  • Table 506. Pulmonary Embolism Drug Sales Others , by Region K Units (2025-2030)
  • Table 507. South America Pulmonary Embolism Drug Sales, by Country K Units (2025-2030)
  • Table 508. South America Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 509. South America Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 510. South America Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 511. South America Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 512. South America Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 513. Brazil Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 514. Brazil Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 515. Brazil Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 516. Brazil Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 517. Brazil Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 518. Argentina Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 519. Argentina Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 520. Argentina Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 521. Argentina Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 522. Argentina Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 523. Rest of South America Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 524. Rest of South America Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 525. Rest of South America Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 526. Rest of South America Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 527. Rest of South America Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 528. Asia Pacific Pulmonary Embolism Drug Sales, by Country K Units (2025-2030)
  • Table 529. Asia Pacific Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 530. Asia Pacific Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 531. Asia Pacific Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 532. Asia Pacific Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 533. Asia Pacific Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 534. China Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 535. China Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 536. China Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 537. China Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 538. China Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 539. Japan Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 540. Japan Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 541. Japan Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 542. Japan Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 543. Japan Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 544. India Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 545. India Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 546. India Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 547. India Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 548. India Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 549. South Korea Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 550. South Korea Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 551. South Korea Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 552. South Korea Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 553. South Korea Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 554. Taiwan Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 555. Taiwan Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 556. Taiwan Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 557. Taiwan Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 558. Taiwan Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 559. Australia Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 560. Australia Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 561. Australia Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 562. Australia Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 563. Australia Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 564. Rest of Asia-Pacific Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 565. Rest of Asia-Pacific Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 566. Rest of Asia-Pacific Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 567. Rest of Asia-Pacific Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 568. Rest of Asia-Pacific Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 569. Europe Pulmonary Embolism Drug Sales, by Country K Units (2025-2030)
  • Table 570. Europe Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 571. Europe Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 572. Europe Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 573. Europe Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 574. Europe Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 575. Germany Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 576. Germany Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 577. Germany Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 578. Germany Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 579. Germany Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 580. France Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 581. France Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 582. France Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 583. France Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 584. France Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 585. Italy Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 586. Italy Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 587. Italy Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 588. Italy Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 589. Italy Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 590. United Kingdom Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 591. United Kingdom Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 592. United Kingdom Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 593. United Kingdom Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 594. United Kingdom Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 595. Netherlands Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 596. Netherlands Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 597. Netherlands Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 598. Netherlands Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 599. Netherlands Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 600. Rest of Europe Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 601. Rest of Europe Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 602. Rest of Europe Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 603. Rest of Europe Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 604. Rest of Europe Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 605. MEA Pulmonary Embolism Drug Sales, by Country K Units (2025-2030)
  • Table 606. MEA Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 607. MEA Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 608. MEA Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 609. MEA Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 610. MEA Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 611. Middle East Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 612. Middle East Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 613. Middle East Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 614. Middle East Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 615. Middle East Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 616. Africa Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 617. Africa Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 618. Africa Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 619. Africa Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 620. Africa Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 621. North America Pulmonary Embolism Drug Sales, by Country K Units (2025-2030)
  • Table 622. North America Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 623. North America Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 624. North America Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 625. North America Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 626. North America Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 627. United States Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 628. United States Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 629. United States Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 630. United States Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 631. United States Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 632. Canada Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 633. Canada Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 634. Canada Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 635. Canada Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 636. Canada Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 637. Mexico Pulmonary Embolism Drug Sales, by Type K Units (2025-2030)
  • Table 638. Mexico Pulmonary Embolism Drug Sales, by Application K Units (2025-2030)
  • Table 639. Mexico Pulmonary Embolism Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 640. Mexico Pulmonary Embolism Drug Sales, by Drug Class K Units (2025-2030)
  • Table 641. Mexico Pulmonary Embolism Drug Sales, by Indictaion K Units (2025-2030)
  • Table 642. Pulmonary Embolism Drug: by Type(USD/Units)
  • Table 643. Research Programs/Design for This Report
  • Table 644. Key Data Information from Secondary Sources
  • Table 645. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pulmonary Embolism Drug: by Type USD Million (2018-2023)
  • Figure 5. Global Pulmonary Embolism Drug: by Application USD Million (2018-2023)
  • Figure 6. Global Pulmonary Embolism Drug: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Pulmonary Embolism Drug: by Drug Class USD Million (2018-2023)
  • Figure 8. Global Pulmonary Embolism Drug: by Indictaion USD Million (2018-2023)
  • Figure 9. South America Pulmonary Embolism Drug Share (%), by Country
  • Figure 10. Asia Pacific Pulmonary Embolism Drug Share (%), by Country
  • Figure 11. Europe Pulmonary Embolism Drug Share (%), by Country
  • Figure 12. MEA Pulmonary Embolism Drug Share (%), by Country
  • Figure 13. North America Pulmonary Embolism Drug Share (%), by Country
  • Figure 14. Global Pulmonary Embolism Drug: by Type K Units (2018-2023)
  • Figure 15. Global Pulmonary Embolism Drug: by Application K Units (2018-2023)
  • Figure 16. Global Pulmonary Embolism Drug: by Distribution Channel K Units (2018-2023)
  • Figure 17. Global Pulmonary Embolism Drug: by Drug Class K Units (2018-2023)
  • Figure 18. Global Pulmonary Embolism Drug: by Indictaion K Units (2018-2023)
  • Figure 19. South America Pulmonary Embolism Drug Share (%), by Country
  • Figure 20. Asia Pacific Pulmonary Embolism Drug Share (%), by Country
  • Figure 21. Europe Pulmonary Embolism Drug Share (%), by Country
  • Figure 22. MEA Pulmonary Embolism Drug Share (%), by Country
  • Figure 23. North America Pulmonary Embolism Drug Share (%), by Country
  • Figure 24. Global Pulmonary Embolism Drug: by Type USD/Units (2018-2023)
  • Figure 25. Global Pulmonary Embolism Drug share by Players 2023 (%)
  • Figure 26. Global Pulmonary Embolism Drug share by Players (Top 3) 2023(%)
  • Figure 27. Global Pulmonary Embolism Drug share by Players (Top 5) 2023(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 33. Accu-Break Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 34. Accu-Break Pharmaceuticals, Inc (United States) Revenue: by Geography 2023
  • Figure 35. Dong-A Socio Holdings Co. Ltd.(South Korea) Revenue, Net Income and Gross profit
  • Figure 36. Dong-A Socio Holdings Co. Ltd.(South Korea) Revenue: by Geography 2023
  • Figure 37. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 39. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Genentech, Inc. (United States) Revenue: by Geography 2023
  • Figure 41. Aspen Pharmacare Holdings Limited (South Africa) Revenue, Net Income and Gross profit
  • Figure 42. Aspen Pharmacare Holdings Limited (South Africa) Revenue: by Geography 2023
  • Figure 43. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Global Pulmonary Embolism Drug: by Type USD Million (2025-2030)
  • Figure 46. Global Pulmonary Embolism Drug: by Application USD Million (2025-2030)
  • Figure 47. Global Pulmonary Embolism Drug: by Distribution Channel USD Million (2025-2030)
  • Figure 48. Global Pulmonary Embolism Drug: by Drug Class USD Million (2025-2030)
  • Figure 49. Global Pulmonary Embolism Drug: by Indictaion USD Million (2025-2030)
  • Figure 50. South America Pulmonary Embolism Drug Share (%), by Country
  • Figure 51. Asia Pacific Pulmonary Embolism Drug Share (%), by Country
  • Figure 52. Europe Pulmonary Embolism Drug Share (%), by Country
  • Figure 53. MEA Pulmonary Embolism Drug Share (%), by Country
  • Figure 54. North America Pulmonary Embolism Drug Share (%), by Country
  • Figure 55. Global Pulmonary Embolism Drug: by Type K Units (2025-2030)
  • Figure 56. Global Pulmonary Embolism Drug: by Application K Units (2025-2030)
  • Figure 57. Global Pulmonary Embolism Drug: by Distribution Channel K Units (2025-2030)
  • Figure 58. Global Pulmonary Embolism Drug: by Drug Class K Units (2025-2030)
  • Figure 59. Global Pulmonary Embolism Drug: by Indictaion K Units (2025-2030)
  • Figure 60. South America Pulmonary Embolism Drug Share (%), by Country
  • Figure 61. Asia Pacific Pulmonary Embolism Drug Share (%), by Country
  • Figure 62. Europe Pulmonary Embolism Drug Share (%), by Country
  • Figure 63. MEA Pulmonary Embolism Drug Share (%), by Country
  • Figure 64. North America Pulmonary Embolism Drug Share (%), by Country
  • Figure 65. Global Pulmonary Embolism Drug: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Johnson & Johnson (United States)
  • Accu-Break Pharmaceuticals, Inc (United States)
  • Dong-A Socio Holdings Co. Ltd.(South Korea)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Genentech, Inc. (United States)
  • Aspen Pharmacare Holdings Limited (South Africa)
  • Pfizer Inc. (United States)
Additional players considered in the study are as follows:
Verseon Corporation (United States) , Cyclopharm Ltd.(Australia) , Jubilant Lifesciences Ltd.(India) , Siemens Medical Solutions, Inc (United States) , Grifols Therapeutics Inc. (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 227 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pulmonary Embolism Drug Market Quantitative research analysis
Global Pulmonary Embolism Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline plc (United Kingdom), Johnson & Johnson (United States), Accu-Break Pharmaceuticals, Inc (United States), Dong-A Socio Holdings Co. Ltd.(South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Genentech, Inc. (United States), Aspen Pharmacare Holdings Limited (South Africa) and Pfizer Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increase in Health Care Spending " is seen as one of major influencing trends for Pulmonary Embolism Drug Market during projected period 2023-2030.
The Pulmonary Embolism Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Pulmonary Embolism Drug Market Report?

Have a Query? Click Here

Other Related Reports

Laboratory Cart Comprehensive Study by Type (Storage Laboratory Cart, Regular Laboratory Cart, Other Laboratory Cart), Application (Medical and Healthcare, Pharmaceutical, Others), Transported Materi...
$ 3650
Anesthesia Disposables Comprehensive Study by Type (LMAs, Breathing Circuits, ETTs, Resuscitators, Anesthesia Face Masks), Application (Care Units, Surgical Centers, Operating Rooms, Pain Clinics), D...
$ 3750
Patient Apparel Comprehensive Study by Type (Surgical Apparel, Non-Surgical Apparel), Application (Hospital, Clinic, Home), Distribution Channel (Online Sales, Offline Sales), Material Type (Cotton/P...
$ 3450
Medical Device Outsourcing Comprehensive Study by Type (Electronics, Raw Materials/ Components, Finished Goods), Application (Orthopedics and Spine, Cardiovascular, Radiology, General Medical Devices...
$ 3650
Grapeseed Oil Comprehensive Study by Type (Mechanically by Pressing, Chemically Extracted), Application (Food Industry, Cosmetics, Supplements and Health-Care, Other), Nature (Organic, Conventional),...
$ 3450
Cytogenetics Media Comprehensive Study by Type (Basal Medium, Complete Medium, Chromosome Medium, Bone Marrow Medium, Others), Application (Cytogenetics Laboratories, Medical Center, Scientific Resea...
$ 3750